<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921568</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1018</org_study_id>
    <nct_id>NCT02921568</nct_id>
  </id_info>
  <brief_title>Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes</brief_title>
  <official_title>Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optos, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Optos, PLC.</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate and compare in-tissue performance of OCT scans on the new
      Optos P200TE, versus the predicate Optos Spectral OCT/SLO device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>retinal thickness</measure>
    <time_frame>completion of the study, up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Nerve Fibre Layer Thickness</measure>
    <time_frame>completion of the study, up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optic Nerve Head Topography</measure>
    <time_frame>completion of the study, up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cup/Disc Ratio</measure>
    <time_frame>completion of the study, up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will be imaged on the P200TE and Spectral OCT/SLO devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P200TE</intervention_name>
    <description>Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectral OCT/SLO</intervention_name>
    <description>Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects 18 years of age or older who have full legal capacity to
             volunteer;

          2. Subjects who have signed the informed consent;

          3. Subjects who can follow the instructions by the clinical staff at the clinical site,
             and can attend examinations on the scheduled examination date;

          4. Subjects who agree to participate in the study;

          5. Subjects with current BSCVA 20/400 or better in the ocular disease study eye(s);

          6. Subjects diagnosed with ocular disease including but not limited to: Macular
             Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Central Serous
             Retinopathy, Macular Hole, Epiretinal Membrane, Macular Edema, Glaucoma, and others in
             the retinal disease study eye(s) as confirmed at the study visit or within the past
             six (6) months.

        Exclusion Criteria:

          1. Subjects unable to tolerate ophthalmic imaging;

          2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;

          3. Subjects without ocular disease in study eye(s), as determined by self-report and/or
             investigator assessment at the study visit;

          4. Subjects with history of leukemia, dementia or multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Ellis, BS, MT</last_name>
      <phone>210-697-2036</phone>
      <phone_ext>2270</phone_ext>
      <email>cathy@mcoaeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Michael Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darren J Bell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Burns, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

